Case Presentation and First-Line Treatment Options in EGFR-Mutant NSCLC

Panelists discuss how: a 47-year-old woman with advanced EGFR-mutant non-–small-cell lung cancer (NSCLC), presenting with brain and liver metastases, embodies the complexity of managing metastatic disease in otherwise healthy, motivated patients. Her symptoms, including cough and weight loss, combined with imaging that revealed multiple metastatic sites, underscore the aggressive nature of EGFR-driven cancers. Molecular testing confirmed an EGFR exon 19 deletion with a TP53 co-mutation, shaping the therapeutic approach and prognosis.

The discussion highlights the evolving treatment landscape for first-line management in EGFR-positive NSCLC. Panelists examine how targeted therapies, particularly tyrosine kinase inhibitors (TKIs) , have transformed care, enabling both systemic and central nervous system (CNS) control. They also emphasize the significance of understanding co-mutations like TP53, which can influence disease behavior and therapeutic durability.

Treatment goals in this case focus on achieving deep and durable responses while maintaining quality of life. Panelists explore the patient’s interest in understanding long-term treatment sequencing, reflecting the growing trend toward shared decision-making and patient empowerment in precision oncology.